Located in Biel (canton of Bern), Mimix Biotherapeutics has invested over a decade in research and development. Their core product, FastSkin, is indicative of the future potential of personalized medicine. While FastSkin remains a focal point, the company’s interests span a wide range of areas, including regenerative medicine, drug development, and cellular agriculture.
At the heart of Mimix’s innovations is the Sound Induced Morphogenesis technology (SIM). This process employs acoustic waves to structure biological materials, such as cells or tissues, into precise three-dimensional constructs. Emulating nature’s intricate design strategies, it offers a novel approach to biomedical applications.
The funding round saw contributions from established investor Heraeus Group and newcomer Asia Jetway Pte. The latter, headquartered in Singapore, is known for its extensive portfolio in healthcare solutions across Southeast Asia, comprising affiliate companies such as LandMover, Shanghai Keyman, and others.
Innovating in the sphere of chronic wound management
The shared vision of these investors aligns with Mimix’s goal of advancing wound treatment methodologies. FastSkin is positioned as a treatment that could potentially optimize patient care and bring about efficiencies in healthcare expenditure.
Marc Thurner, the CEO of Mimix, stated, “We are thrilled to have the support of Heraeus Group and Asia Jetway, as we work to bring our innovative wound treatment to market. Their expertise and resources will be invaluable to accelerate go-to-market and internationalization plans.”
Given the conclusion of this financial milestone, Mimix is a step closer to realizing its mission of innovating in the sphere of chronic wound management. As part of its future roadmap, Mimix is actively seeking collaborations and partnerships across both industry and academia, aiming to further leverage its proprietary technologies in the broader biomedical landscape.
